Compare Uranium Energy Corp (UEC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Uranium Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Uranium Energy Corp trades at $11.63 (market cap $5.74B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| UEC | XBI | |
|---|---|---|
Market Cap | $5.74B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $20.14 | $169.55 |
52-Week Low | $9.04 | $93.43 |
Enterprise Value | $5.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UEC is trading at $11.89, up 3.03% today, with a bullish technical signal despite negative profitability metrics. The company reported a net loss of $87.66 million in 2025 with revenue of $66.84 million, though it beat Q4 2025 EPS expectations. Analyst sentiment remains strongly positive with 87.5% buy ratings, supported by institutional interest including BlackRock's recent $432.68 million investment.
The outlook for UEC is mixed, with strong analyst support and nuclear energy tailwinds offset by persistent losses and negative margins. Key risks include execution challenges and uranium price volatility, while opportunities lie in the growing nuclear power sector and institutional backing. The stock trades near recent support levels with technical indicators suggesting potential near-term strength.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
